India's first ever 'ABO - Incompatible (Non-matching blood groups) Kidney Transplantation' using the 'Immunoadsorption Technique' performed in Hyderabad based Kamineni Hospital
with the minimum cost of Rs. 200 -250 is available at all laboratories and helps determining calcification thereby identifying risk for cardiovascular events
Adding to this, the FM has also extended the Rashtriya Swasthya Bima Yojana to poor and marginal workers and Mahatma Gandhi National Rural Employment Guarantee Act beneficiaries, besides workers in the beedi industry and other unorganised sectors.
However, the minister imposed a service tax on services provided by centrally air-conditioned hospitals with 25 or more beds.
The wholly-owned subsidiary of Opto Circuits India, Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, has been awarded a contract to deploy Powerheart® AEDs at U.S. Postal Inspection Service sites across the United States. The U.S.
Last week, the Drug Controller General of India (DCGI) sent a notice to Piramal Healthcare to stop airing the advertisement of its emergency contraceptive drug ‘i-pill’ disguised as an awareness campaign, a health official said.
Reckitt Benckiser India is the Indian arm of the UK based company which manufacturers Dettol antiseptic soap, Disprin, Motein mosquito repellent and Cherry Blossom shoe polish. The company has now agreed to buy the Indian ointment and personal care company based in Ahmadabad – Paras Pharma – for Rs. 3, 260 crore($724 million).
Fortis Healthcare’s President - Medical Strategy & Quality, Dr. Narottam Puri, signed an agreement with Denise Bucumi Nkurunziza, the First Lady of Burundi, who is also the current President of Foundation ‘Buntu’. The foundation is a non-profit organization registered under the Government of Burundi.
Malvinder Mohan Singh and Shivinder Mohan Singh-promoted Fortis Global Healthcare Holdings announced on Sunday that it will acquire the healthcare businesses of Hong Kong-listed Quality Healthcare Asia (QHA). The cumulative amount considered for this acquisition is around Rs. 882 crore.
J Harinarayan, Chairman, IRDA said, “I do hope there will be an impact on revenues. Ultimately, the idea of guidelines is to have an impact. My concern for the insurance industry is not what is going to happen in 2010-11, but to see that the industry remains healthy and be sustainable,”
However, in recent years, there has been growth to enhance the health of girls and women in India. Yet, too many still die due to reasons that can completely be prevented. Every year, 68,000 women in India die from pregnancy-related issues, more than any other country.
The minister said that these clubs will help inculcate values of good health and sanitation among children. He announced this at the launch of the National School Sanitation Initiative which is being undertaken by the Union Ministry for Human Resource Development, Union Ministry of Urban Development, CBSE and GTZ.
Further to this news, the report also stated that 77% of health expenses in rural areas and 70% in urban areas are on medicines alone. The study suggests that in a year, out-of-pocket medical costs alone push 2.2% of the entire population below the poverty line.
According to sources close to the development, the promoter group increased stake by 0.69% to 35.47% via open market procurements in the last two trading sessions. Committed to raising their stake further, these promoters believe that the group’s business has potential to grow in profits along with valuation in the future.
EMEA and IDC France have completed a special study focused on the combined implications of changes in the French hospital system, the role of ICT, the delivery of care, and the competitive ICT environment.
The announced removal of administrative barriers under the Canada-US Tax Treaty for investors such as non-resident venture capital funds will ease the way for investment in Canadian biotechnology firms says trade industry association BIOTECanada.
AstraZeneca’s shares were down today following the failure of the company’s experimental cancer drug Recentin, generically known as cediranib, against Roche's Avastin. The drug did not meet its primary endpoint in the Horizon phase III study, a negative result expected by analysts.
When Tony Falco, PhD, CEO and Founder of Resonant Medical, was doing clinical and research work at Montreal’s McGill University Health Center on developing a digital x-ray-based detector for imaging soft tissue, he realized something critical.